Azitra
Update in progressAZTR (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on precision dermatology using engineered proteins and topical live biotherapeutics to treat skin diseases in the United States. Its assets include ATR-04 (Phase 1/2) for cancer therapy–related papulopustular rash, ATR-12 (Phase 1b/2a) for Netherton syndrome, and ATR-01 (IND-enabling) for ichthyosis vulgaris, all based on engineered Staphylococcus epidermidis strains. It has a Bayer joint development agreement. Founded 2014, Branford, CT.
Company score
- Sentiment
- 0.03
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- -0.22
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.01
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE American (ASE)
- LocationUnited States
- CEOMr. Francisco D. Salva
- Founded2014
- Employees13
- Websiteazitrainc.com
Identifiers
- ISINUS05479L2034
- FIGIBBG00GDC73T8
- CUSIP05479L302
- CIK0001701478